Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.

Also Known As:

Networked: 27623 relevant articles (1327 outcomes, 4790 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ferrara, Napoleone: 77 articles (06/2015 - 01/2002)
2.	Carmeliet, Peter: 69 articles (11/2015 - 02/2002)
3.	Rini, Brian I: 56 articles (11/2015 - 04/2004)
4.	Wang, Wei: 54 articles (11/2015 - 03/2002)
5.	Jain, Rakesh K: 53 articles (11/2015 - 03/2002)
6.	Campochiaro, Peter A: 53 articles (11/2015 - 02/2002)
7.	Zhang, Wei: 52 articles (12/2015 - 01/2002)
8.	Harris, Adrian L: 52 articles (04/2015 - 04/2002)
9.	Shibuya, Masabumi: 50 articles (10/2015 - 03/2002)
10.	Alitalo, Kari: 49 articles (06/2015 - 03/2002)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2011 - "We found that the ratio of VEGF-A/sFLT-1 was increased not only in murine but also in human MA, and F-gene-deleted recombinant Sendai virus (rSeV/dF)-mediated secretion of human sFLT-1 by DCs augmented not only the activity of DCs themselves, but also dramatically improved the survival of tumor-bearing animals associated with enhanced CTL activity and its infiltration to peritoneal tumors. " 08/01/2014 - "An important question for the pediatric oncology research community, pharmaceutical companies, and regulatory agencies to address in planning for future clinical trials is whether existing data support a role for VEGF pathway targeted agents in contributing to a therapeutic pathway to cure for children with cancer." 12/01/2011 - "Pharmacological targeting of blood vessels, mainly through the VEGF signaling pathway, has proven effective in normalizing tumor vessels. " 01/01/2009 - "VEGF levels were highest in those who did not achieve complete remission after cancer therapy. " 11/01/2006 - "Since the tumor vascular network can impact the efficacy of anti-cancer therapies, these results suggest that VEGF expression may be important to consider in the treatment of cancer."
2.	Colorectal Neoplasms (Colorectal Cancer) 08/15/2015 - "The clinical management of colorectal cancer patients has significantly improved because of the identification of novel therapeutic targets such as EGFR and VEGF. " 01/01/2011 - "Moreover, high P-LVD and high VEGF expression were significant negative prognostic parameters associated with a shorter disease-free interval in stage I colorectal cancer. " 11/01/2002 - "Early postoperative serum VEGF levels show significant fall and may help to identify the oncological status of colorectal cancer resections." 01/01/2015 - "Therefore, the simultaneous targeting of EGFR/VEGF and COX-2 may aid in blocking mCRC progression and improve the efficacy of existing therapies in colorectal cancer. " 02/01/2010 - "Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients."
3.	Anoxia (Hypoxia) 10/17/2006 - "Levels of VEGF and of hypoxia-inducible factor 1alpha, elevated in the human MECs under hypoxia, were dramatically reduced or even suppressed in the presence of the ITPP-loaded RBCs. " 09/20/2012 - "In addition, to explore whether VEGF secreted by HIF-1α-AA-modified BMSCs plays an important role in preventing hypoxia-induced apoptosis and the possible mechanism involved, exogenous VEGF were applied and the similar protective effects on PC12 cells were observed in vitro. " 04/01/2011 - "On the one hand, neoangiogenesis driven by VEGF, if intact, ameliorates hypoxia, on the other, VEGF is a potent pro-inflammatory mediator and neoangiogenesis, if defective because interference by other pathologies exaggerates injury. " 07/01/2010 - "The mechanism seems to involve in inhibiting hypoxia-mediated activation of p-ERK1/2, it leads to a marked decrease in hypoxia-induced HIF-1alpha protein accumulation and VEGF secretion. " 06/01/2010 - "Combination treatment resulted in a marked inhibition of HIF-1 alpha expression levels in hypoxic cells and caused a significant reduction in the expression of activated phosphorylated AKT, ERK1/2, p-BAD and VEGF in both normoxia and hypoxia with greater levels of inhibition in hypoxia. "
4.	Macular Degeneration (Age-Related Maculopathy) 01/01/2009 - "Since anti-VEGF treatment has been proven to achieve a significant improvement of visual acuity in a cohort of patients with neovascular age-related macular degeneration (AMD), macular surgery and particularly the macular translocation with 360 degrees retinotomy (FMT: full macular translocation) have lost their former popularity. " 09/01/2011 - "We retrospectively studied 40 eyes of 40 patients with neovascular age-related macular degeneration who were treated successfully with intravitreal anti-vascular endothelial growth factor injection. " 12/01/2008 - "Since the introduction of anti-VEGF drugs for the treatmet of CNV in age-related macular degeneration (AMD), visual acuity can be stabilised or improved in a significant number of patients. " 09/01/2003 - "These results strengthen the evidence for a critical role of the VEGF-KDR system in the development of CNV, indicating that KDR selective inhibitor might be beneficial for the treatment of intraocular angiogenic diseases, including age-related macular degeneration." 08/01/2014 - "Although anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration (AMD) results in improved vision overall, loss of substantial vision can occur. "
5.	Ischemia 03/01/2006 - "Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia--a case report." 02/16/2001 - "Tissue ischemia and/or VEGF may stimulate capillary sprouting, but this response does not translate to a significant improvement in collateral flow. " 01/01/2015 - "In this work we report on therapeutic efficacy of CS from mouse ADSC transduced to express human vascular endothelial growth factor 165 a/a isoform (VEGF165), which showed potency to restore perfusion and protect tissue in a model of limb ischemia. " 01/01/2009 - "The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium." 01/01/2003 - "However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	bevacizumab
3.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
4.	ranibizumab (Lucentis)
5.	Epidermal Growth Factor Receptor (EGF Receptor)
6.	Messenger RNA (mRNA)
7.	Retinaldehyde (Retinal)
8.	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
9.	Small Interfering RNA (siRNA)
10.	Protein-Tyrosine Kinases (Tyrosine Kinase)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Heterologous Transplantation (Xenotransplantation)
4.	Lasers (Laser)
5.	Intravitreal Injections